CN1835911A - 合成n-[(s)-1-羧基丁基]-(s)-丙氨酸酯的新方法及该化合物在合成培哚普利中的用途 - Google Patents

合成n-[(s)-1-羧基丁基]-(s)-丙氨酸酯的新方法及该化合物在合成培哚普利中的用途 Download PDF

Info

Publication number
CN1835911A
CN1835911A CNA2004800235340A CN200480023534A CN1835911A CN 1835911 A CN1835911 A CN 1835911A CN A2004800235340 A CNA2004800235340 A CN A2004800235340A CN 200480023534 A CN200480023534 A CN 200480023534A CN 1835911 A CN1835911 A CN 1835911A
Authority
CN
China
Prior art keywords
formula
compound
synthetic method
synthesizing
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2004800235340A
Other languages
English (en)
Other versions
CN100460382C (zh
Inventor
F·布雷亚尔
C·菲吉耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Publication of CN1835911A publication Critical patent/CN1835911A/zh
Application granted granted Critical
Publication of CN100460382C publication Critical patent/CN100460382C/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30Preparation of optical isomers
    • C07C227/32Preparation of optical isomers by stereospecific synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/321,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)

Abstract

本发明公开合成式(I)衍生物的方法,在式(I)中,R代表直链或支链(C1-C6)烷基基团。本发明的方法可用于合成培哚普利及其药学可接受盐。

Description

合成N-[(S)-1-羧基丁基]-(S)-丙氨酸酯的新方法及该化合物在合成培哚 普利中的用途
本发明涉及合成N-[(S)-1-羧基丁基]-(S)-丙氨酸酯的方法,以及它们在合成培哚普利及其药学可接受盐中的用途。
更具体地讲,本发明涉及合成下式(I)衍生物以及它们与一种或多种无机或有机酸或碱的加成盐的新方法:
Figure A20048002353400051
式中R代表直链或支链(C1-C6)烷基基团。
根据本发明方法得到的式(I)化合物可用于合成下式(II)培哚普利及其药学可接受盐:
培哚普利及其盐具有重要的药理学性质。
它们的主要性质是抑制血管紧张素I转化酶(或激肽酶II),因此,一方面它们能够阻止十肽血管紧张素I转化成八肽血管紧张素II(血管收缩剂),另一方面它们能够防止缓激肽(血管舒张药)降解成失活肽。
这两种作用有助于培哚普利在心血管疾病、特别是动脉高血压和心脏供血不足中发挥有益的作用。
欧洲专利EP 0 049 658中描述了培哚普利、其制备方法及其在治疗中的用途。
鉴于这种化合物的药学价值,重要的是能够采用竞争力强的合成方法获得式(I)中间体,特别是能够选择性地获得非对映异构体(S,S),其产率高,纯度极佳,而且还易转换成工业规模。
人们已经知道了一些制备式(I)化合物的方法。
-杂志《Tet.Lett.》,1982,23(16),1677-80描述了在氰基硼氢化钠存在下,在乙醇中,使2-氧代戊酸乙酯与丙氨酸叔-丁酯反应获得式(I)化合物(R=乙基)。
-专利EP 0 309 324描述了在二甲基甲酰胺中,在三乙胺存在下,使丙氨酸苄酯与α-溴代戊酸乙酯反应得到式(I)化合物(R=乙基)。
-专利EP 0 308 340和EP 0 308 341描述了在水中,在氢、披钯炭和氢氧化钠存在下,使戊氨酸乙酯盐酸盐与丙酮酸反应得到式(I)化合物(R=乙基)。
本申请人现在已研制一种式(I)衍生物的新工业合成方法。
更具体地讲,本发明涉及合成式(I)化合物的方法,其特征在于使下式(III)吗啉酮:
Figure A20048002353400061
式中P代表氨基官能团保护基团,
*或者在碱存在下与溴化物或三氟甲磺酸烯丙酯反应得到具有(3S,5S)构型的下式(IV)化合物:
Figure A20048002353400062
式中P如前面所定义,
该化合物在披钯炭的存在下进行氢化,
*或者与碘代丙烷反应得到具有(3S,5S)构型的下式(V)化合物:
Figure A20048002353400071
式中P如前面所定义,
该化合物经LiOH作用,然后经酯化试剂作用,得到下式(VI)化合物:
Figure A20048002353400072
式中R和P如前面所定义,
该化合物与氧化剂进行反应,在氨基官能团去保护后得到式(I)化合物。
在本发明可使用的氨基官能团保护基团中,作为非限制性实例可以列举叔-丁氧基羰基和苄氧基羰基基团。优选的P基团是叔-丁氧基羰基。
在式(III)化合物与溴化物或三氟甲磺酸烯丙酯的反应可使用的碱中,作为非限制性实例可以列举二异丙基氨化锂(LDA)、双(三甲基甲硅烷基)氨化钠(NaHMDS)和叔丁醇钾。
在制备式(VI)化合物可使用的酯化试剂中,作为优选可以列举下式(VII)化合物:
                    R-X    (VII)
式中R如式(I)中所定义,X代表三氟甲磺酸酯、对甲苯磺酸酯或甲磺酸酯基团或卤素原子,优选碘原子。
希望得到其中R代表甲基的式(I)化合物时,酯化试剂也可以是重氮甲烷。
在式(VI)化合物的氧化反应可使用的氧化剂中,作为非限制性实例可以列举在RuCl3存在下的NaIO4
这种氧化反应也可以分两步进行,第一步,例如在Swern条件下,将式(VI)化合物转化成相应的醛,第二步,例如用KMnO4将这种醛氧化成相应的羧酸。
在化学或药品工业中,特别是在培哚普利合成中,式(V)和(VI)化合物是用作合成中间体的新产品,因此是本发明的组成部分。
优选的R基团是乙基。
使用(S)-N-苄基丙氨醇可以得到式(III)化合物,在三乙胺存在下,使(S)-N-苄基丙氨醇与溴代乙酸乙酯进行反应,在苄基基团裂解后得到(S)-N-(乙氧基羰基甲基)丙氨醇,它再用如前面定义的P基团进行保护,然后通过与对-甲苯磺酸的反应进行环化。
实施例:N-[(S)-乙氧羰基-1-丁基]-(S)-丙氨酸,盐酸盐
步骤A:(3S,5S)-3-烯丙基-5-甲基-2-氧代-4-吗啉羧酸叔丁酯:
向反应器中装入200g(5S)-5-甲基-2-氧代-4-吗啉甲酸叔丁酯和700ml四氢呋喃,然后将这种溶液冷却到-60℃,再添加700ml 2M二异丙基氨化锂在四氢呋喃和庚烷中的溶液,同时将该反应介质的温度保持低于-40℃。在反应1小时后,添加225g烯丙基溴,同时将反应介质的温度保持低于-30℃,搅拌3h。
然后使反应化合物升到室温,用氯化铵水溶液进行水解,用乙醚提取,其醚相用水洗涤。
该醚相经干燥分离得到的(3S,5S)-3-烯丙基-5-甲基-2-氧代-4-吗啉甲酸叔丁酯可原样用于后续步骤。
步骤B:(3S,5S)-5-甲基-3-丙基-2-氧代-4-吗啉甲酸叔丁酯:
向氢化器中装入200g在前面步骤得到的化合物在乙醇中的溶液,然后装入5g 10%Pd/C。在大气压与室温下进行氢化直到吸收理论量的氢。
过滤除去催化剂,然后干燥分离(3S,5S)-5-甲基-3-丙基-2-氧代-4-吗啉甲酸叔丁酯。
步骤C:(2S)-2-{(叔-丁氧基羰基)[(1S)-2-羟基-1-甲基乙基]-氨基}-戊酸乙酯
向反应器中装入200g在前面步骤得到的化合物、500ml乙腈、500ml水和500ml己烷,然后添加33g氢氧化锂水合物,在0℃搅拌3h。
干燥所述反应混合物,得到的锂盐溶解在1.5升二甲基甲酰胺中,然后在室温下用122g碘乙烷进行处理。
在蒸去二甲基甲酰胺后,已干燥的残留物用乙醇处理,用二氧化硅过滤,得到(2S)-2-{(叔-丁氧基羰基)[(1S)-2-羟基-1-甲基乙基]-氨基}-戊酸乙酯,其产率60%。
步骤D:N-[(S)-乙氧基羰基-1-丁基]-N-(叔-丁氧基羰基)-(S)-丙氨酸
向反应器中装入500ml二氯甲烷、500ml水和500ml乙腈,然后添加141g高碘酸钠和1.35g三氯化钌水合物。搅拌lh,再快速添加200g在前面步骤得到的化合物。反应结束后,用硅藻土过滤,洗涤有机相,并将其蒸发至干,得到N-[(S)-乙氧基羰基-1-丁基]-N-(叔-丁氧基羰基)-(S)-丙氨酸。
步骤E:N-[(S)-乙氧基羰基-1-丁基]-(S)-丙氨酸,盐酸盐:
向反应器中装入200g在前面步骤得到的化合物和1.5升乙酸乙酯,然后将反应介质的温度调到0℃,通入盐酸气流30分钟。在室温下搅拌一夜后,生成的沉淀经过滤、漂洗和干燥得到N-[(S)-乙氧基羰基-1-丁基]-(S)-丙氨酸盐酸盐,为定量产率。

Claims (9)

1.合成下式(I)化合物的方法:
Figure A2004800235340002C1
式中R代表直链或支链(C1-C6)烷基基团,
其特征在于使下式(III)吗啉酮:
式中P代表氨基官能团的保护基团,
*或者在碱存在下与溴化物或三氟甲磺酸烯丙酯反应得到具有(3S,5S)构型的下式(IV)化合物:
式中P如前面所定义,
该化合物在披钯炭的存在下进行氢化,
*或者与碘代丙烷反应得到下式(V)化合物:
Figure A2004800235340002C4
式中P如前面所定义,
该化合物经LiOH作用,然后经酯化试剂作用,得到下式(VI)化合物:
式中R和P如前面所定义,
该化合物与氧化剂进行反应,在氨基官能团去保护后得到式(I)化合物。
2.根据权利要求1所述的合成方法,该方法得到其中R代表乙基的式(I)衍生物。
3.根据权利要求1或2所述的合成方法,其特征在于P代表叔-丁氧基羰基。
4.根据权利要求1-3中任一项所述的合成方法,其特征在于式(III)化合物与溴化物或三氟甲磺酸烯丙酯反应所使用的碱是二异丙基氨化锂、双(三甲基甲硅烷基)氨化钠或叔丁醇钾。
5.根据权利要求1-4中任一项所述的合成方法,其特征在于酯化试剂是碘乙烷。
6.根据权利要求1-5中任一项所述的合成方法,其特征在于氧化剂是在RuCl3存在的NaIO4
7.式(V)化合物:
式中P代表叔-丁氧基羰基。
8.式(VI)化合物:
Figure A2004800235340003C3
式中P代表叔-丁氧基羰基,且R代表乙基。
9.使用式(I)化合物合成培哚普利或其药学可接受盐的方法,其特征在于根据权利要求1所述方法得到所述的式(I)化合物。
CNB2004800235340A 2003-09-01 2004-08-31 合成n-[(s)-1-羧基丁基]-(s)-丙氨酸酯的新方法及该化合物在合成培哚普利中的用途 Expired - Fee Related CN100460382C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03292145A EP1362845B1 (fr) 2003-09-01 2003-09-01 Nouveau procédé de synthèse des esters de la N-((S)-1-carboxybutyl)-(S)-alanine et application à la synthèse du perindopril
EP03292145.4 2003-09-01
PCT/FR2004/002213 WO2005023755A1 (fr) 2003-09-01 2004-08-31 Nouveau procede de synthese des esters de la n-[(s)-1-carboxybutyl]-(s)-alanine et application a la synthese du perindopril

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200710167579A Division CN100577652C (zh) 2003-09-01 2004-08-31 合成n-[(s)-1-羧基丁基]-(s)-丙氨酸酯的中间体及该化合物在合成培哚普利中的用途

Publications (2)

Publication Number Publication Date
CN1835911A true CN1835911A (zh) 2006-09-20
CN100460382C CN100460382C (zh) 2009-02-11

Family

ID=29266057

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200710167579A Expired - Fee Related CN100577652C (zh) 2003-09-01 2004-08-31 合成n-[(s)-1-羧基丁基]-(s)-丙氨酸酯的中间体及该化合物在合成培哚普利中的用途
CNB2004800235340A Expired - Fee Related CN100460382C (zh) 2003-09-01 2004-08-31 合成n-[(s)-1-羧基丁基]-(s)-丙氨酸酯的新方法及该化合物在合成培哚普利中的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN200710167579A Expired - Fee Related CN100577652C (zh) 2003-09-01 2004-08-31 合成n-[(s)-1-羧基丁基]-(s)-丙氨酸酯的中间体及该化合物在合成培哚普利中的用途

Country Status (29)

Country Link
US (1) US7361757B2 (zh)
EP (1) EP1362845B1 (zh)
JP (1) JP4616833B2 (zh)
KR (1) KR100735198B1 (zh)
CN (2) CN100577652C (zh)
AR (1) AR045545A1 (zh)
AT (1) ATE445588T1 (zh)
AU (1) AU2004270432B8 (zh)
BR (1) BRPI0413901B1 (zh)
CA (1) CA2536926C (zh)
CY (1) CY1109822T1 (zh)
DE (1) DE60329648D1 (zh)
DK (1) DK1362845T3 (zh)
EA (1) EA009980B1 (zh)
EG (1) EG25738A (zh)
ES (1) ES2334900T3 (zh)
GE (1) GEP20094650B (zh)
HK (2) HK1096378A1 (zh)
MA (1) MA28018A1 (zh)
MX (1) MXPA06002229A (zh)
MY (1) MY139073A (zh)
NO (1) NO20061152L (zh)
NZ (1) NZ545337A (zh)
PL (1) PL211801B1 (zh)
PT (1) PT1362845E (zh)
SI (1) SI1362845T1 (zh)
UA (1) UA81179C2 (zh)
WO (1) WO2005023755A1 (zh)
ZA (1) ZA200601427B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE031058T2 (en) * 2004-03-29 2017-06-28 Servier Lab A method of producing a solid pharmaceutical composition
SI21800A (sl) 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek sinteze perindoprila
EP1792896A1 (en) 2005-12-01 2007-06-06 KRKA, tovarna zdravil, d.d., Novo mesto Process for the preparation of perindopril and salts thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2503155A2 (fr) * 1980-10-02 1982-10-08 Science Union & Cie Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
FR2620699B1 (fr) * 1987-09-17 1990-06-01 Adir Procede de synthese d'alpha amino acides n alkyles et de leurs esters. application a la synthese de carboxyalkyl dipeptides
FR2807037B1 (fr) * 2000-03-31 2002-05-10 Adir NOUVEAU PROCEDE DE SYNTHESE DES ESTERS DE LA N-[(s)-1- CARBOXYBUTYL]-(S)-ALANINE ET APPLICATION A LA SYNTHESE DU PERINDOPRIL
FR2807430B1 (fr) * 2000-04-11 2002-05-17 Adir Nouveau procede de synthese des esters de la n-[(s)-1- carboxybutyl]-(s)-alanine et application a la synthese du perindopril

Also Published As

Publication number Publication date
PL211801B1 (pl) 2012-06-29
KR100735198B1 (ko) 2007-07-03
MXPA06002229A (es) 2006-05-17
ES2334900T3 (es) 2010-03-17
JP4616833B2 (ja) 2011-01-19
AU2004270432B8 (en) 2008-02-21
ATE445588T1 (de) 2009-10-15
PT1362845E (pt) 2009-11-05
DE60329648D1 (de) 2009-11-26
CA2536926A1 (fr) 2005-03-17
MA28018A1 (fr) 2006-07-03
AR045545A1 (es) 2005-11-02
CA2536926C (fr) 2010-06-22
SI1362845T1 (sl) 2010-01-29
PL379626A1 (pl) 2006-10-30
HK1096378A1 (en) 2007-06-01
KR20060060710A (ko) 2006-06-05
GEP20094650B (en) 2009-03-25
AU2004270432B2 (en) 2007-12-06
ZA200601427B (en) 2007-05-30
MY139073A (en) 2009-08-28
CY1109822T1 (el) 2014-09-10
EP1362845A2 (fr) 2003-11-19
UA81179C2 (en) 2007-12-10
JP2007504203A (ja) 2007-03-01
NZ545337A (en) 2009-12-24
CN100460382C (zh) 2009-02-11
CN100577652C (zh) 2010-01-06
BRPI0413901B1 (pt) 2016-11-29
EA009980B1 (ru) 2008-04-28
BRPI0413901A (pt) 2006-10-24
HK1118285A1 (en) 2009-02-06
US7361757B2 (en) 2008-04-22
EG25738A (en) 2012-06-20
AU2004270432A1 (en) 2005-03-17
EP1362845A3 (fr) 2004-03-31
CN101143855A (zh) 2008-03-19
DK1362845T3 (da) 2010-01-18
EP1362845B1 (fr) 2009-10-14
US20060252958A1 (en) 2006-11-09
WO2005023755A1 (fr) 2005-03-17
EA200600501A1 (ru) 2006-08-25
NO20061152L (no) 2006-03-10

Similar Documents

Publication Publication Date Title
CN1296355C (zh) 合成培哚普利及其药学上可接受的盐的方法
CN1926102A (zh) N-保护的4-酮脯氨酸衍生物的制备方法
CN1040648C (zh) 1-脱氨基-8-d-精氨酸抗利尿激素的制造方法
CN1533398A (zh) 合成(2S,3aS,7aS)-1-[(S)-丙氨酰基]-八氢-1H-吲哚-2-甲酸衍生物的新方法及其在合成哌林多普利中的用途
CN1300111C (zh) 制备高纯度培哚普利的方法及在其合成中有用的中间体
CN1057835A (zh) 由二酮基哌嗪生产天冬氨酰苯丙氨酸甲酯的方法和新的中间体及其衍生物
CN1176903C (zh) 合成n-[(s)-1-羧丁基]-s-丙氨酸酯的方法及其用于合成培哚普利的用途
CN1835911A (zh) 合成n-[(s)-1-羧基丁基]-(s)-丙氨酸酯的新方法及该化合物在合成培哚普利中的用途
CN1171855C (zh) 合成n-[(s)-1-羧基丁基]-(s)-丙氨酸酯的新方法及其在合成培哚普利中的用途
CN1148847A (zh) 氨基磺酸衍生物,它们在合成假肽中的应用及制备方法
CN1802384A (zh) 培哚普利及其可药用盐的新合成方法
CN1835965A (zh) 合成培哚普利及其药学可接受盐的新方法
CN1839147A (zh) 合成培哚普利及其药学上可接受盐的新方法
CN1145638C (zh) 天冬氨酰二肽酰胺衍生物和增甜剂
CN100383160C (zh) 合成培哚普利及其药学上可接受盐的新方法
CA1246550A (en) Amide derivatives
CN1826351A (zh) 合成培哚普利及其药学可接受盐的新方法
CN1753907A (zh) (2S,3aS,7aS)-1-[(S)-丙氨酰]-八氢-1H-吲哚-2-甲酸衍生物的新合成方法及其在合成培哚普利中的应用
CN1826352A (zh) 合成培哚普利及其药学可接受盐的新方法
CN1240712C (zh) 制备酪-丝-亮三肽的方法
CN1753869A (zh) (2S,3aS,7aS)-全氢吲哚-2-甲酸和其酯的新合成方法及其在合成培哚普利中的应用
CN1753906A (zh) 培哚普利和其可药用盐的新合成方法
CN1364163A (zh) 2-氨基甲基-4-氰基-噻唑的制备方法
JPH1192496A (ja) 1−〔n2−((s)−エトキシカルボニル)−3−フェニルプロピル)−n6−トリフルオロアセチル〕−l−リシル−l−プロリンの単離方法およびその単離生成物
CN1116627A (zh) 由三氟甲基酮类得到的新型肽、其制备方法以及含肽的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1096378

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1096378

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090211

Termination date: 20180831

CF01 Termination of patent right due to non-payment of annual fee